US Antitrust Lawsuit Against Healthcare Giants Stalled Amidst Jurisdictional Dispute
Ohio Attorney General David Yost’s Lawsuit Accusing Express Scripts, Humana, and Others of Collusion Faces Jurisdictional Hurdles.
A legal battle over alleged collusion to inflate prescription drug prices has hit a roadblock as healthcare giants, including Express Scripts and Humana, contest the jurisdiction in which the lawsuit should be heard. Ohio Attorney General David Yost filed the lawsuit in March, accusing several major health care companies of violating state antitrust laws and the Ohio Deceptive Practices Act.
Express Scripts, a pharmacy benefit manager (PBM), stands accused alongside corporate relatives Cigna and Evernorth, as well as Ascent Health Services and Prime Therapeutics. The lawsuit alleges that these entities, through Ascent, engaged in anti-competitive practices that artificially raised the cost of prescription drugs.
Express Scripts, acting as a PBM, plays a crucial role in drug transactions by representing insurers. PBMs, including the accused companies, are exempt from the federal anti-kickback statute due to their ability to negotiate substantial discounts from drug manufacturers in exchange for including the products on lists of covered drugs.
Yost contends that by operating through Ascent, the companies effectively shared pricing information, creating an environment where they could avoid competition and exploit pharmacies. The lawsuit suggests that such collaboration harms market competition, ultimately resulting in higher prescription drug prices.
Read more: NOVEL PRIVACY CONCERNS IN HEALTHCARE ANTITRUST
The legal battle takes an interesting turn as the accused companies seek to move the case from state court to federal court, where they hope to secure a dismissal. Despite being sued under Ohio law, the companies are pushing for a federal forum, a move that could impact the trajectory of the case and its potential outcomes.
Ascent Health Services, formed by Express Scripts in 2019 amid calls for increased transparency in PBM dealings with drugmakers, has also drawn attention for its unique structure. Despite all its customers being based in the United States, Express Scripts strategically headquartered significant parts of the company in Switzerland, known for its stringent bank-secrecy protections.
Additionally, the lawsuit implicates Prime Therapeutics, which acquired a minority stake in Ascent in December 2019, as well as Humana Pharmacy Solutions, a smaller PBM with ties to Ascent.
Source: Ohio Capital Journal
Featured News
Judge Allows FTC Antitrust Case Against Amazon to Move Forward
Oct 1, 2024 by
CPI
SAP Leader Urges Caution on EU AI Rules, Warns of Competitive Disadvantage
Oct 1, 2024 by
CPI
Colorado’s Grocery Workers Unite to Oppose $24.6 Billion Supermarket Merge
Oct 1, 2024 by
CPI
Canada’s Competition Bureau Warns Businesses of Tougher Enforcement
Oct 1, 2024 by
CPI
Top Antitrust Lawyers Launch New Boutique Firm
Oct 1, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Refusal to Deal
Sep 27, 2024 by
CPI
Antitrust’s Refusal-to-Deal Doctrine: The Emperor Has No Clothes
Sep 27, 2024 by
Erik Hovenkamp
Why All Antitrust Claims are Refusal to Deal Claims and What that Means for Policy
Sep 27, 2024 by
Ramsi Woodcock
The Aspen Misadventure
Sep 27, 2024 by
Roger Blair & Holly P. Stidham
Refusal to Deal in Antitrust Law: Evolving Jurisprudence and Business Justifications in the Align Technology Case
Sep 27, 2024 by
Timothy Hsieh